摘要
目的:观察重组人血管内皮抑制素联合顺铂胸腔灌注治疗恶性胸腔积液的疗效及安全性。方法:100例恶性胸腔积液患者随机分为Ⅰ、Ⅱ、Ⅲ组,分别注入顺铂、重组人血管内皮抑制素及二者联用,每周1次,3周后评价疗效及生活质量。结果:在治疗胸水有效率方面,Ⅰ、Ⅱ组分别与Ⅲ组比较有显著性差异(P=0.007;P=0.020),Ⅰ组与Ⅱ组比较无显著性差异(P=0.715);在生活质量改善率方面,Ⅰ、Ⅱ组分别与Ⅲ组比较有显著性差异(P=0.036;P=0.048),Ⅰ组与Ⅱ组比较无显著性差异(P=0.918)。结论:重组人血管内皮抑制素联合顺铂治疗恶性胸腔积液疗效显著,不增加化疗的毒副作用。
OBJECTIVE：To evaluate the efficacy and safety of recombinant human endostatin plus cisplatin（thoracic cavity perfusion）for malignant pleural effusion. METHODS：A total of 100 cases with malignant pleural effusion were randomly assigned to receive either cisplatin（GroupⅠ）or rh-endostatin（GroupⅡ）or cisplatin plus rh-endostatin（Group Ⅲ）once a week. The efficacy and quality of life were evaluated after 3- week treatment. RESULTS：There were significant differences between GroupⅠand Group Ⅲ（P=0.007）and between Group Ⅱ and Group Ⅲ（P=0.020）with regard to the effective rate in pleural effusion,but the difference between GroupⅠand Group Ⅱ was not significant（P=0.715）. With regard to the rate of improvement of quality of life,there were statistical significances between GroupⅠand GroupⅢ（P=0.036）and between GroupⅡand GroupⅢ（P=0.048）; whereas no significant differences were noted between GroupⅠand GroupⅡ（P=0.918）. CONCLUSION：Addition of rh-endostain to cisplatin shows remarkable efficacy yet without increasing toxic effect in the treatment of malignant pleural effusion.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第14期1308-1310,共3页
China Pharmacy
